On May 7, 2020, Entos Pharmaceuticals announced a partnership with Precision NanoSystems, Inc., (PNI), a global leader in enabling transformative nanomedicines, to produce clinical grade vaccines and therapeutics using PNI’s NanoAssemblr™ GMP System.

Entos develops next generation nucleic acid-based therapies using the proprietary Fusogenix drug delivery system, a proteo-lipid vehicle (PLV) that delivers molecules, intact and unmodified, directly into the cytosol of target cells. Entos has recently launched a DNA vaccine rapid prototyping project around the development of a pan-coronavirus DNA vaccine, with the aim of broad availability within one year. To reach this ambitious target, Entos will incorporate PNI’s NanoAssemblr GMP System into the manufacturing suite at the Alberta Cell Therapy Manufacturing (ACTM) Facility, located in the University of Alberta’s Li Ka Shing Centre for Health Research Innovation. This will enable the production of clinical grade Fusogenix genetic nanomedicines such as Covigenix, Entos’s pan-coronavirus Fusogenix DNA vaccine.

Entos develops next generation nucleic acid-based therapies using the proprietary Fusogenix drug delivery system, a proteo-lipid vehicle (PLV) that delivers molecules, intact and unmodified, directly into the cytosol of target cells. Entos has recently launched a DNA vaccine rapid prototyping project around the development of a pan-coronavirus DNA vaccine, with the aim of broad availability within one year. To reach this ambitious target, Entos will incorporate PNI’s NanoAssemblr GMP System into the manufacturing suite at the Alberta Cell Therapy Manufacturing (ACTM) Facility, located in the University of Alberta’s Li Ka Shing Centre for Health Research Innovation. This will enable the production of clinical grade Fusogenix genetic nanomedicines such as Covigenix, Entos’s pan-coronavirus Fusogenix DNA vaccine.